Larka

Larka Strategic Advisor Of Keensight Capital During The Acquisition Of 3P Bio

About

PR KS 3P.jpg
 

Larka acted as Strategic advisor to Keensight Capital on its investment in 3P Biopharmaceuticals.

31 July 2019

Larka is pleased to announce that it performed the Commercial Due-Diligence – CDD – for Keensight Capital, the new majority shareholder of 3P Biopharmaceuticals. Larka advised Keensight Capital on all relevant strategic, commercial and business aspects of the transaction. In addition, Larka also performed the Technical, Quality & Regulatory Due-Diligence.

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments, acquired Infarco’s majority stake in 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization – CDMO – specialized in the process development and GMP manufacturing of biologics for both microbial and mammalian expression systems.

Founded in 2006 and based near Pamplona, Spain, 3P Biopharmaceuticals employs 240 people and offers a complete biologics production service, from preclinical and clinical stages, all the way to full-scale commercial manufacturing.

As strategic advisor, Larka performed the Commercial Due-Diligence to support Keensight Capital during the acquisition of 3P Biopharmaceuticals. Larka “Industry consulting” division also performed the Technical, Quality & Regulatory Due-Diligence.

Javier Lopez Moras, Director at Keensight Capital, said: “We are proud to be the new shareholders of 3P Biopharmaceuticals, one of the European leaders in the biologics CDMO space. We have been happy to work with Larka on this investment opportunity. Pierre-Anthony Brioir and his team confirmed once again the level of excellence and expertise they have in this field.”

 Pierre-Anthony Brioir, Director at Larka, commented: “After our successful collaboration last year on another transaction in this field, we are very proud to have worked again with Keensight on this new successful deal. 3P Biopharmaceuticals has a strong growth potential, with a wide range of services covering the whole value chain, from preclinical work to commercial supply. Combined with the highly skilled and experienced team of Keensight, 3P Biopharmaceuticals should become a major CDMO player in Europe in the coming years.”

Contacts

  • Pierre-Anthony Brioir, Director at Larka, +33 650-630-286, pabrioir@larka.fr

  • Adrien Chalmont, Manager at Larka, +33 621-006-115, achalmont@larka.fr

About Larka

Founded in 1993, Larka is an “Industry & Strategy” consulting and M&A advisory firm exclusively dedicated to the Pharma & Biotech industry. Larka combines strong value-creation strategic advisory with in-depth industrial & technical expertise. With over 100 consultants, Larka covers the whole value chain and helps Private Equity Firms, Pharma & Biotech companies, and Contract Services Providers – Analytical testing Labs, CROs, CDMOs, CMOs – build sustainable and profitable businesses globally.

About Keensight Capital

 Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital’s team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million. Drawing on its expertise in the Information Technology/Internet and Healthcare/Wellbeing sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision. www.keensightcapital.com

About 3P Biopharmaceuticals

 3P Biopharmaceuticals is a leading CDMO specialized in the process development and GMP manufacturing of biological products. 3P offers its customers solutions at all stages of development: from initial steps to analytics development, preclinical and clinical phases, and commercial production. Its extensive experience, flexibility and willingness to adapt to client needs – underpinned by the technology and team to pull it all together – is what positions 3P as a truly differentiated company on the international stage. www.3pbio.com